The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.

Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.

In the randomized, sham-controlled ARTEMIS study, patients will receive either a dose of ixo-vec or a standard care regimen of anti-VEGF Eylea.